NEOMED Announces a New Collaboration with Johnson & Johnson Innovation to
Advance Drug Discovery and Development Programs
MONTREAL, Dec. 10, 2013 /CNW Telbec/ - NEOMED, a leading drug discovery and
development public-private partnership in Canada, today announced a new
collaboration with Johnson & Johnson Innovation, and its affiliate Janssen
Inc. Canada, to accelerate the transition of university and biotechnology
company early-stage research into potential treatments.
Through this collaboration, teams of experienced technical experts at both the
Johnson & Johnson Innovation Center in Boston, Massachusetts and NEOMED will
work together to identify and advance medically important projects. These
projects will come from NEOMED's network of partnered academic institutions
and biotechnology companies, as well as from Canadian, US and international
drug discovery groups.
"NEOMED welcomes the opportunity to work with the pharmaceutical researchers
at Johnson & Johnson Innovation in this innovative business model," said Dr.
Max Fehlmann, President and CEO of NEOMED and the NEOMED Institute. "Johnson &
Johnson Innovation has been a pioneer in large Pharma external research and
the reinvention of the drug discovery enterprise. We look forward to their
valuable contribution in support of our mission of helping academia to
efficiently translate early innovations into high value drug candidates."
Johnson & Johnson Innovation is the third global pharmaceutical company
collaborator to join NEOMED since its founding in late 2012. The other global
pharmaceutical company partners are AstraZeneca and Pfizer.
AboutNEOMED and the NEOMED Institute
NEOMED was set up one year ago to support the transition of promising drug
discovery technologies and therapeutic approaches emerging from academic and
biotechnology companies, and to bring these emerging therapeutics to IND or
Phase II human proof-of-concept, which are stages when the drug candidates
become most attractive to the biopharmaceutical companies. NEOMED is jointly
funded by AstraZeneca, Pfizer and the Ministère des Finances et de
l'Économie du Québec.
NEOMED's sole focus is drug discovery, and preclinical and early clinical drug
development. It has a team of scientists with industry-level expertise and
capabilities ranging from medicinal chemistry, drug target validation studies
through animal pharmacology, toxicology and clinical trials design and
NEOMED is established within the NEOMED Institute, a state-of-the-art R&D
facility in the Montreal Technoparc. The Institute acts as an open-access drug
discovery hub hosting drug discovery and development research companies,
providing a unique environment to foster innovation, collaboration and
For more information, please visit: www.neomed.ca
Mounia Azzi, PhD Director, Scientific Affairs NEOMED (514) 909-7714
To view this news release in HTML formatting, please use the following URL:
NI: BTC VNT
-0- Dec/10/2013 13:00 GMT
Press spacebar to pause and continue. Press esc to stop.